For COVID-Impacted Trials, Investigators Should Practice Remote Assessments Beforehand, US FDA Says

 
• By Sue Sutter

Agency emphasizes feasibility and consistency when it comes to remote administration of clinician-reported and performance outcome assessments in studies disrupted by the pandemic; latest guidance update also discusses remote site monitoring, as well as alternative procurement and administration of investigational products.

Sea stones laid out in the form of a circle
Remote outcome assessments should be conducted in a consistent manner to minimize variability, US FDA says. • Source: Shutterstock

More from Clinical Trials

More from R&D